Zoetis Inc. (ZTS) PEG Ratio: 2.04
Is Zoetis Inc.’s PEG ratio high or low?
Zoetis Inc.'s PEG ratio of 2.04 is 46% below its 5-year average of 3.78, near the low end of its 5-year range (2.04–6.34).
The PEG ratio for Zoetis Inc. (ZTS) is 2.04. It is below its 12-month average by 31.08% (2.96).
ZTS PEG Ratio Chart
ZTS Average PEG Ratio Chart
ZTS Current vs Average PEG Ratio Chart
ZTS PEG Ratio Metrics
PEG RATIO
2.04
PEG RATIO AVG TTM
2.96
PEG RATIO AVG 3Y
3.83
PEG RATIO AVG 5Y
3.78
PEG RATIO AVG 10Y
3.70
PEG RATIO AVG 15Y
3.04
PEG RATIO AVG 20Y
3.04
CURRENT VS TTM AVG
-31.08%
CURRENT VS 3Y AVG
-46.77%
CURRENT VS 5Y AVG
-45.98%
CURRENT VS 10Y AVG
-44.89%
CURRENT VS 15Y AVG
-32.85%
CURRENT VS 20Y AVG
-32.85%
ZTS Competitors' PEG Ratio
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zoetis Inc. (ZTS) | — | 2.04 | 2.96 | 3.83 | 3.78 |
| Centene Corporation (CNC) | $31.94B | N/A | 0.18 | 0.16 | 0.16 |
| Agilent Technologies, Inc. (A) | $37.17B | 9.41 | 7.52 | 13.88 | 11.21 |
| IQVIA Holdings Inc. (IQV) | $30.60B | 6.34 | 8.50 | 5.12 | 3.87 |
| DexCom, Inc. (DXCM) | $29.24B | 0.66 | 19.99 | 10.91 | 8.76 |
| Biogen Inc. (BIIB) | $29.00B | 0.34 | 0.34 | 0.24 | 0.23 |
| Veeva Systems Inc. (VEEV) | $26.73B | 1.42 | 1.47 | 5.64 | 5.88 |
| Humana Inc. (HUM) | $43.78B | N/A | 0.45 | 0.32 | 0.59 |
| IDEXX Laboratories, Inc. (IDXX) | $44.47B | 2.30 | 4.40 | 3.66 | 3.12 |
| Waters Corporation (WAT) | $23.83B | 75.62 | 75.62 | 40.78 | 27.51 |
Growth-Adjusted Valuation
PEG Ratio
2.04
P/E Ratio
13.5
Zoetis Inc. PEG Ratio Formula & Definition
PEG Ratio = PE Ratio / Earnings Growth Rate
The PEG ratio adjusts the PE ratio for expected earnings growth. A PEG near 1 is often considered fairly valued relative to growth.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Zoetis Inc. PEG Ratio FAQ
- What is the PEG ratio for Zoetis Inc. (ZTS)?
- The PEG ratio for ZTS stock is 2.04.
- Is Zoetis Inc.'s PEG ratio high or low?
- Zoetis Inc.'s PEG ratio of 2.04 is 46% below its 5-year average of 3.78, near the low end of its 5-year range (2.04–6.34).
- What is the TTM average PEG ratio for Zoetis Inc. (ZTS)?
- The TTM average PEG ratio for ZTS stock is 2.96.
- What is the 3Y average PEG ratio for Zoetis Inc. (ZTS)?
- The 3Y average PEG ratio for ZTS stock is 3.83.
- What is the 5Y average PEG ratio for Zoetis Inc. (ZTS)?
- The 5Y average PEG ratio for ZTS stock is 3.78.
- What is the 10Y average PEG ratio for Zoetis Inc. (ZTS)?
- The 10Y average PEG ratio for ZTS stock is 3.70.
- What is the 15Y average PEG ratio for Zoetis Inc. (ZTS)?
- The 15Y average PEG ratio for ZTS stock is 3.04.
- What is the 20Y average PEG ratio for Zoetis Inc. (ZTS)?
- The 20Y average PEG ratio for ZTS stock is 3.04.
Zoetis Inc. PEG Ratio History
| DATE | PEG RATIO |
|---|---|
| 2025-12-31 | 2.04 |
| 2024-12-31 | 3.88 |
| 2023-12-31 | 3.07 |
| 2022-12-31 | 6.34 |
| 2021-12-31 | 2.30 |
| 2020-12-31 | 5.03 |
| 2019-12-31 | 6.94 |
| 2018-12-31 | 0.42 |
| 2017-12-31 | 6.78 |
| 2016-12-31 | 0.22 |
| 2014-12-31 | 2.49 |
| 2013-12-31 | 2.02 |
| 2012-12-31 | 0.50 |
| 2011-12-31 | 0.50 |
Related Metrics
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Kristin C. Peck